CREB3L1: A Potential Drug Target for Neurodegenerative Diseases

Target Name: CREB3L1

NCBI ID: G90993

CREB3L1

CREB3L1: A Potential Drug Target for Neurodegenerative Diseases

CREB3L1, also known as CAMP responsive element binding protein 3-like 1, is a protein that plays a crucial role in the regulation of gene expression in the brain. It is a member of the CREB/CBP gene family, which is known for its role in the control of DNA replication, gene transcription, and cell growth.

CREB3L1 is a 21-kDa protein that is expressed in various tissues of the brain, including cortical and subcortical regions. It is highly conserved, with a calculated pI of 12.9 and a predicted localization in the cytoplasm. CREB3L1 is involved in the regulation of gene expression by binding to specific DNA sequences, known as response elements, located in the genomic DNA.

CREB3L1 functions as a negative regulator of transcription factors that are involved in the development and progression of neural circuits. It has been shown to interact with several transcription factors, including CBF, p300, andCREB2. These interactions may play a role in the regulation of neuronal excitability and synaptic plasticity.

In addition to its role in gene regulation, CREB3L1 has also been shown to play a role in the regulation of cellular processes such as cell adhesion, migration and invasion. It has been shown to interact with several cytoskeleton proteins, including beta-tubulin, microbiome. Tubulin and actin.

Overexpression of CREB3L1 can lead to a variety of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, etc. In treating these diseases, researchers are likely to consider CREB3L1 as a potential drug target or biomarker.

Some researchers believe that overexpression of CREB3L1 may be a factor in neurodegenerative diseases. For example, in a 2019 study, researchers found that CREB3L1 was overexpressed in the brains of people with Alzheimer's disease. Additionally, other studies have shown that CREB3L1 is overexpressed in the brains of Parkinson's disease patients.

Therefore, the researchers believe that CREB3L1 is a potential drug target or biomarker that can be used to treat neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Protein Name: CAMP Responsive Element Binding Protein 3 Like 1

Functions: Transcription factor involved in unfolded protein response (UPR). Binds the DNA consensus sequence 5'-GTGXGCXGC-3' (PubMed:21767813). In the absence of endoplasmic reticulum (ER) stress, inserted into ER membranes, with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane. In response to ER stress, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBTPS2. The released N-terminal cytosolic domain is translocated to the nucleus to effect transcription of specific target genes. Plays a critical role in bone formation through the transcription of COL1A1, and possibly COL1A2, and the secretion of bone matrix proteins. Directly binds to the UPR element (UPRE)-like sequence in an osteoblast-specific COL1A1 promoter region and induces its transcription. Does not regulate COL1A1 in other tissues, such as skin (By similarity). Required to protect astrocytes from ER stress-induced cell death. In astrocytes, binds to the cAMP response element (CRE) of the BiP/HSPA5 promoter and participate in its transcriptional activation (By similarity). Required for TGFB1 to activate genes involved in the assembly of collagen extracellular matrix (PubMed:25310401)

The "CREB3L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CREB3L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets